Literature DB >> 12624629

Genome-wide linkage analysis of von Willebrand factor plasma levels: results from the GAIT project.

Juan Carlos Souto1, Laura Almasy, Jose Manuel Soria, Alfonso Buil, William Stone, Mark Lathrop, John Blangero, Jordi Fontcuberta.   

Abstract

High plasma levels of von Willebrand factor (vWF) have been associated with the risk of thromboembolic disease. As a complex trait, this phenotype must be influenced by genetic and environmental factors. Among the genetic factors, only the ABO gene located on chromosome 9q34 has been clearly linked to the plasma levels of vWF. This locus explains about 30-40% of the genetic variability. Therefore, the source of the majority of the genetic component remains to be identified. To search for these unknown loci, we conducted a genomewide linkage screen for genes affecting normal variation in vWF levels in 21 Spanish families as part of the GAIT (Genetic Analysis of Idiopathic Thrombophilia) Project. The results showed that the strongest linkage signal (LOD =3.46, p = 0.00003) for vWF was found on chromosome 9q34 at the DNA marker D9S290, where the ABO gene is located. Additional suggestive linkage signals were found on chromosomes 2q23.2 (LOD = 1.65, p = 0.003) and 1p36.13 (LOD =1.32, p = 0.007). After refining the linkage analysis, conditional to the ABO genotype, three additional loci on chromosomes 5, 6 and 22 showed LOD scores higher than 1, suggesting the presence of other genes linked to vWF levels. Curiously, no linkage signals were detected in other chromosome regions previously associated with vWF levels (like the structural VWF gene on 12p13.2 or Lewis blood group gene on 19q13). These results indicate that these loci are not important genetic determinants of the normal variation of vWF levels. Our results indicate that the ABO locus is the major genetic determinant of the plasma levels of the vWF in Spanish population. It is possible that there are other potential regions on chromosomes 1, 2, 5, 6 and 22 that influence this thrombosis risk factor. However, the structural vWF gene itself has a very low influence (if any) on the plasma levels of vWF.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12624629

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  21 in total

1.  Genome-wide studies of von Willebrand factor propeptide identify loci contributing to variation in propeptide levels and von Willebrand factor clearance.

Authors:  A B Ozel; B McGee; D Siemieniak; P M Jacobi; S L Haberichter; L C Brody; J L Mills; A M Molloy; D Ginsburg; J Z Li; K C Desch
Journal:  J Thromb Haemost       Date:  2016-08-19       Impact factor: 5.824

2.  Enhanced VWF biosynthesis and elevated plasma VWF due to a natural variant in the murine Vwf gene.

Authors:  Heidi L Lemmerhirt; Jordan A Shavit; Gallia G Levy; Suzanne M Cole; Jeffrey C Long; David Ginsburg
Journal:  Blood       Date:  2006-07-27       Impact factor: 22.113

3.  Genome-wide association study for endothelial growth factors.

Authors:  Wolfgang Lieb; Ming-Huei Chen; Martin G Larson; Radwan Safa; Alexander Teumer; Sebastian E Baumeister; Honghuang Lin; Holly M Smith; Manja Koch; Roberto Lorbeer; Uwe Völker; Matthias Nauck; Henry Völzke; Henri Wallaschofski; Douglas B Sawyer; Ramachandran S Vasan
Journal:  Circ Cardiovasc Genet       Date:  2014-12-31

4.  The endothelial cell receptor stabilin-2 regulates VWF-FVIII complex half-life and immunogenicity.

Authors:  Laura L Swystun; Jesse D Lai; Colleen Notley; Ilinca Georgescu; A Simonne Paine; Jeff Mewburn; Kate Nesbitt; Kai Schledzewski; Cyrill Géraud; Julia Kzhyshkowska; Sergij Goerdt; Wilma Hopman; Robert R Montgomery; Paula D James; David Lillicrap
Journal:  J Clin Invest       Date:  2018-08-20       Impact factor: 14.808

5.  Prospective study of ABO blood type and the risk of pulmonary embolism in two large cohort studies.

Authors:  Brian M Wolpin; Christopher Kabrhel; Raphaëlle Varraso; Peter Kraft; Eric B Rimm; Samuel Z Goldhaber; Carlos A Camargo; Charles S Fuchs
Journal:  Thromb Haemost       Date:  2010-09-30       Impact factor: 5.249

6.  Third Åland islands conference on von Willebrand disease, 26-28 September 2012: meeting report.

Authors:  E Berntorp; B Fuchs; M Makris; R Montgomery; V Flood; J S O'Donnell; A B Federici; D Lillicrap; P James; U Budde; M Morfini; P Petrini; S Austin; C Kannicht; V Jiménez-Yuste; C Lee
Journal:  Haemophilia       Date:  2013-03       Impact factor: 4.287

7.  ABO blood group influences transfusion and survival after cardiac surgery.

Authors:  Ian J Welsby; Barbara Phillips-Bute; Joseph P Mathew; Mark F Newman; Richard Becker; Sunil Rao; Carmelo A Milano; Mark Stafford-Smith
Journal:  J Thromb Thrombolysis       Date:  2014-10       Impact factor: 2.300

Review 8.  Current controversies in the diagnosis and management of von Willebrand disease.

Authors:  Anne T Neff
Journal:  Ther Adv Hematol       Date:  2015-08

9.  Modifiers of von Willebrand factor identified by natural variation in inbred strains of mice.

Authors:  Jordan A Shavit; Ani Manichaikul; Heidi L Lemmerhirt; Karl W Broman; David Ginsburg
Journal:  Blood       Date:  2009-09-29       Impact factor: 22.113

10.  Linkage analysis identifies a locus for plasma von Willebrand factor undetected by genome-wide association.

Authors:  Karl C Desch; Ayse B Ozel; David Siemieniak; Yossi Kalish; Jordan A Shavit; Courtney D Thornburg; Anjali A Sharathkumar; Caitlin P McHugh; Cathy C Laurie; Andrew Crenshaw; Daniel B Mirel; Yoonhee Kim; Cheryl D Cropp; Anne M Molloy; Peadar N Kirke; Joan E Bailey-Wilson; Alexander F Wilson; James L Mills; John M Scott; Lawrence C Brody; Jun Z Li; David Ginsburg
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-24       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.